'America's Nobel' prizes go to sleep and hemophilia researchers, and to Michael J. Fox for Parkinson's advocacy

This year's Lasker Awards — coveted prizes for biomedical research that are sometimes called "America's Nobel Prizes" — have gone to scientists behind fundamental discoveries in sleep science and to researchers who developed a groundbreaking treatment for hemophilia.

Additionally, a Lasker Award for public service went to actor Michael J. Fox for his advocacy for patients with Parkinson's disease that has helped advance research into the neurodegenerative condition.

The prizes, each of which comes with an honorarium of $250,000, will be presented in person Sept. 17 in New York City. The awardees were announced Wednesday (Sept. 9) by the Lasker Foundation, which was established in 1942 by the philanthropists and health advocates Albert and Mary Lasker.

The first of the three awards, called the Albert Lasker Basic Medical Research Award , went to two scientists who independently discovered a key substance in the brain that helps control the sleep-wake cycle and is missing in people with some forms of narcolepsy — the neurological disorder marked by excessive daytime sleepiness and, sometimes, cataplexy (sudden episodes of muscle weakness).

The researchers — Dr. Emmanuel Mignot of the Stanford University School of Medicine and Masashi Yanagisawa of the University of Tsukuba in Japan — arrived at the discovery through different approaches. Mignot wanted to understand the underlying causes of narcolepsy, while Yanagisawa was investigating a curious class of receptors that were known as "orphans" because the chemicals that activated those receptors were unknown.

"We never thought we would end up in sleep," Yanagisawa told Live Science. "This was a kind of biochemical fishing expedition."

In particular, Yanagisawa was interested in proteins at the surface of cells called G protein-coupled receptors (GPCRs). When the right chemicals are plugged into these receptors, they trigger a chain of events within cells. Various compounds that activate GPCRs had already been found to be useful as drugs , but there were many receptors with unknown triggers.

Get the world’s most fascinating discoveries delivered straight to your inbox.